Automate Your Wheel Strategy on RDHL
With Tiblio's Option Bot, you can configure your own wheel strategy including RDHL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RDHL
- Rev/Share 0.0007
- Book/Share -0.0004
- PB -0.5518
- Debt/Equity -0.076
- CurrentRatio 0.536
- ROIC 3.8184
- MktCap 4805389.0
- FreeCF/Share -0.0008
- PFCF -0.5124
- PE -0.3125
- Debt/Assets 0.0197
- DivYield 0
- ROE 6.326
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
Published: July 01, 2025 by: PRNewsWire
Sentiment: Neutral
Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and Ramsay Hospital Research Foundation Precision medicine approach: The 60-patient Phase 2 study uses the PCPro™ lipid biomarker test to identify patients with poor prognosis most likely to benefit from the combination Led by Professor Lisa Horvath, the study is expected to recruit people at sites across Australia and New Zealand Prostate cancer is the second most diagnosed cancer in the world with around 1.5 million new cases per year, causing almost 400,000 deaths 1 . Prostate …
Read More
RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum
Published: February 27, 2025 by: PRNewsWire
Sentiment: Neutral
Guy Goldberg, RedHill's Chief Business Officer, presents today a business update at the European Life Sciences CEO Forum The update covers: The recent out-licensing of RHB-102 [1] to Hyloris (Euronext Brussels: HYL) in a potential $60 million plus royalties deal Initiation of the Bayer-funded Phase 2 clinical study of opaganib [2] in combination with Bayer's (ETR: BAYN) darolutamide in advanced prostate cancer Status of the U.S. government-supported pipeline programs and expected 2025 catalysts Significant commercial progress with Talicia®: Additional marketing authorization applications in new markets being evaluated Discussions ongoing focused on significant cost of goods (COGs) reduction Inclusion as first-line …
Read More
RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
- Hyloris will pay RedHill an upfront payment and up to $60 million in potential milestone payments, plus up to mid-20s percent royalties on revenues, in return for exclusive rights to develop and commercialize RHB-102 (Bekinda®) across all indications and territories outside the United States, Canada and Mexico - Recent positive UK MHRA advice provided a clear pathway for a UK Marketing Authorization Application (MAA). If approved, RHB-102 could be the first oral 24-hour extended-release ondansetron for the treatment of chemotherapy/radiotherapy-induced nausea and vomiting (CINV/RINV) - RedHill intends to continue development of RHB-102 for FDA approval in the U.S., if …
Read More
About RedHill Biopharma Ltd. (RDHL)
- IPO Date 2013-01-07
- Website https://www.redhillbio.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Dror Ben-Asher
- Employees 35